News & Events zu Ardelyx, Inc. (ARDX)ARDXArdelyx, Inc.

Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer

Beam Therapeutics (BEAM) announced the appointment of Eric Foster as chief commercial officer. Foster will lead Beam's commercial organization and strategy as the company advances multiple product candidates across its hematology and genetic disease franchises toward potential launches. Foster brings more than 25 years of commercial leadership experience across biotechnology and specialty pharmaceuticals and most recently served as chief commercial officer at Ardelyx (ARDX).

Ardelyx Reports Q2 Revenue of $118.13M

Reports Q2 revenue $118.13M, consensus $121.64M. "In the second quarter of 2026, we delivered combined revenue of $118 million, up 31% year over year, the largest quarterly revenue in our Company's history," said Mike Raab, President and Chief Executive Officer of Ardelyx. "XPHOZAH had an excellent quarter, reinforcing the strength of our commercial foundation. The demand for IBSRELA was strong despite revenues below our expectations resulting from significantly increased utilization management processes from payors that we are actively addressing. The underlying fundamentals of our business remain robust and considering the recent market dynamics, we are updating our full year and future growth outlook. We are generating significant revenue, and we are moving towards profitability in 2027. We are a high-growth company with the demonstrated ability to effectively manage through external challenges, and I have full confidence in our team's ability to execute. Our commitment to patients and to creating long-term shareholder value remains steadfast."

Ardelyx Reports Q1 Revenue of $94.47M, Exceeds Expectations

Reports Q1 revenue $94.47M, consensus $92.61M. "In the first quarter of 2026, Ardelyx continued our strong commercial execution which coupled with our strengthening cash position allows us to conduct multiple IBSRELA clinical trials, advance development of our next-generation NHE3 inhibitor, RDX10531, and purposefully explore various avenues to build a significant and sustainable pipeline of important medicines," said Mike Raab, President and Chief Executive Officer of Ardelyx. "IBSRELA is the cornerstone for the company we're building and is on the path to becoming a blockbuster by achieving at least one billion dollars in revenue in 2029 with continued strong growth thereafter. We are in a position of financial strength, providing flexibility to allocate capital across the business, accelerate commercial momentum, and drive intrinsic long-term value for the Company, our patients, and our shareholders."